Overview

Phase 3 Study of MAP0004 in Adult Migraineurs

Status:
Completed

Trial end date:
2011-01-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double blind, placebo controlled, parallel group study of MAP0004 in adult migraineurs. Subjects will self administer study drug in the outpatient setting.

Phase:

Phase 3

Details

Lead Sponsor:

Allergan

Collaborator:

MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan